Navigation Links
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
Date:1/15/2014

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014.  The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Solta and expected timing of the transaction.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.  Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Solta's business will be adversely impacted during the pendency of the acquisition; the risk that the operations of the two companies will not be integrated successfully; and other risks and uncertainties, including those detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission ("SEC") and in the case of Valeant, the Canadian Securities Administrators ("CSA"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, which have been filed with the SEC and in the case of Valeant, the CSA.  The forward-looking statements in this press release are qualified by these risk factors. The companies assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Additional Information and Where to Find It

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Solta. Valeant filed a Tender Offer Statement on Schedule TO with the SEC on December 23, 2013. Solta filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on December 23, 2013.   Stockholders of Solta are urged to read the tender offer materials (including the Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as amended (to the extent applicable), because they contain important information which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, have been made available to all stockholders of Solta at no expense to them.  The Tender Offer Statement and the Solicitation/Recommendation Statement are available to all stockholders of Solta free of charge at the website maintained by the SEC at www.sec.gov. In addition, the tender offer statement and other documents that Valeant files with the SEC are and will be made available to all stockholders of Solta free of charge at www.valeant.com.  The Solicitation/Recommendation Statement and the other documents filed by Solta with the SEC are, and will be, made available to all stockholders of Solta free of charge at www.Solta.com.  

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
2. Valeant Pharmaceuticals To Present At Industry Conferences
3. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
4. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
6. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
7. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
8. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
9. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
10. Valeant Pharmaceuticals Announces Continuance
11. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company (NYSE: ... decided the Alimta® (pemetrexed disodium) vitamin regimen patent would not ... UK, France , Italy ... dilute the product only with dextrose solution.  ... the UK Court of Appeal held that Lilly,s patent would ...
(Date:2/12/2016)... 12, 2016 Indiso ... den ungedeckten medizinischen Bedarf bei Lungen- und ... klinischen Forschungsprogramms bekannt. Das Programm, das sich ... ihrer respiratorischen Funktionen und anderer klinischer Parameter. ... Medizintechnikunternehmen, das sich auf den ungedeckten medizinischen ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips on ... of Rama - Dr. Frederick Lenz. , According to Publisher Roger Cantu, ... teacher for teaching and helping others. Valentine’s Day celebrates love in all its ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn from ... will show what to expect when they come knocking this year. But that takes time. ...
(Date:2/12/2016)... CITY, California (PRWEB) , ... February 12, 2016 , ... ... announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre ... healthy way to stay hydrated before the big event. The invitation-only gifting suite, held ...
(Date:2/12/2016)... ... 2016 , ... Every winter, someone is killed, injured or loses a home ... Center, part of the Allegheny Health Network, has partnered with Etna Volunteer Fire ... Need Space” campaign. , “Space Heaters Need Space” aims to bring awareness ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert ... to Know in 2016 . The list consists of physicians establishing, leading and partnering ... this list. , An Ambulatory Surgery Center, also known as an ASC, is ...
Breaking Medicine News(10 mins):